Oak Ridge Investments LLC Has $989,000 Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Oak Ridge Investments LLC lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.3% in the 1st quarter, HoldingsChannel reports. The fund owned 1,831 shares of the company’s stock after selling 211 shares during the quarter. Oak Ridge Investments LLC’s holdings in IDEXX Laboratories were worth $989,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in IDXX. Valley National Advisers Inc. increased its position in IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after acquiring an additional 22 shares in the last quarter. Riverview Trust Co acquired a new stake in shares of IDEXX Laboratories during the 1st quarter worth approximately $26,000. Geo Capital Gestora de Recursos Ltd acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth approximately $28,000. DSM Capital Partners LLC acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $33,000. Finally, Venturi Wealth Management LLC grew its position in shares of IDEXX Laboratories by 226.3% during the 4th quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock worth $34,000 after buying an additional 43 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 1.8 %

NASDAQ IDXX traded up $8.51 during trading on Friday, reaching $486.00. 381,823 shares of the stock traded hands, compared to its average volume of 492,080. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The stock’s 50-day moving average price is $500.35 and its 200 day moving average price is $524.55. The firm has a market cap of $40.14 billion, a price-to-earnings ratio of 47.05, a price-to-earnings-growth ratio of 3.90 and a beta of 1.32.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The firm had revenue of $964.10 million for the quarter, compared to analyst estimates of $965.43 million. Analysts predict that IDEXX Laboratories, Inc. will post 11.03 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on IDXX. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Stifel Nicolaus lowered their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research report on Monday, June 24th. Morgan Stanley lowered their price target on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research report on Tuesday, May 14th. Barclays lowered their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. Finally, StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, June 14th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $586.63.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Bruce L. Claflin sold 200 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the transaction, the director now owns 161 shares of the company’s stock, valued at $87,068.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 2.18% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.